74761-39-0

Usage

Uses

Used in Pharmaceutical Industry:
(2S,3S)-2-((methoxycarbonyl)amino)-3-methylpentanoic acid is used as a building block for the synthesis of peptides and peptidomimetics, which are essential components in the development of new pharmaceuticals. Its versatile reactivity and biological activity make it an important compound in the field of pharmaceutical research and development.
Used in Organic and Medicinal Chemistry:
(2S,3S)-2-((methoxycarbonyl)amino)-3-methylpentanoic acid is used as a starting material for the production of pharmaceuticals and other bioactive compounds. Its ability to modify the properties of peptide-based drugs helps improve their stability, bioavailability, and therapeutic effects, making it a valuable tool in drug discovery and development.

Upstream product

• 73-32-5 L-isoleucine 
• 79-22-1 methyl chloroformate 
• 73-32-5 L-isoleucine 
• 111398-44-8 N-methoxycarbonyl-L-valine 

Downstream Products

• 5860-63-9 (S)-4-((S)-sec-butyl)oxazolidine-2,5-dione 
• 198905-13-4 N'-[(2S,3S)-2-Hydroxy-3-((2S,3S)-2-methoxycarbonylamino-3-methyl-pentanoylamino)-4-phenyl-butyl]-N'-(4-pyridin-2-yl-benzyl)-hydrazinecarboxylic acid tert-butyl ester 
• 1056135-19-3 methyl (1S,2S)-1-[({(1S,2S,4S)-1-benzyl-4-[(tert-butoxycarbonyl)amino]-2-hydroxy-5-phenylpentyl}amino)carbonyl]-2-methylbutylcarbamate 
• 854754-16-8 methyl (1S,2S)-1-{[((1S,3S,4S)-1-benzyl-4-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-hydroxy-5-phenylpentyl)amino]carbonyl}-2-methylbutylcarbamate 
• 857904-27-9 Methyl (1S,2S)-1-[(2-benzylhydrazino)carbonyl]-2-methylbutylcarbamate 
• 857904-28-0 Tert-butyl (1S,2S)-1-benzyl-3-(1-benzyl-2-{(2S,3S)-2-[(methoxycarbonyl)amino]-3-methylpentanoyl}hydrazino)-2-hydroxypropylcarbamate 
• 857904-21-3 Tert-butyl (1S,2S)-1-benzyl-2-hydroxy-3-{2-{(2S,3S)-2-[(methoxycarbonyl)amino]-3-methylpentanoyl}-1-[4-(2-pyridinyl)benzyl]hydrazino}propylcarbamate 
• 1242088-66-9 C₄₂H₅₂N₈O₆ 
• 1428135-48-1 C₄₅H₅₈N₈O₆Si 
• 1428136-45-1 C₄₄H₅₆N₈O₆Si 
• 1615709-27-7 (2S,3aS,6aS)-benzyl 1-((2S,3S)-2-(methoxycarbonylamino)-3-methylpentanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylate 
• 1615709-28-8 (2S,3aS,6aS)-1-((2S,3S)-2-(methoxycarbonylamino)-3-methylpentanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid 
• 1228670-70-9 C₄₂H₆₀N₈O₆ 

Relevant academic research and scientific papers

Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere

The design, synthesis, and X-ray structural analysis of hybrid HIV-1 protease inhibitors (PIs) containing bis-tetrahydrofuran (bis-THF) in a pseudo-C2-symmetric dipeptide isostere are described. A series of PIs were synthesized by incorporating bis-THF of darunavir on either side of the Phe-Phe isostere of lopinavir in combination with hydrophobic amino acids on the opposite P2/P2′ position. Structure-activity relationship studies indicated that the bis-THF moiety can be attached at either the P2 or P2′ position without significantly affecting potency. However, the group on the opposite P2/P2′ position had a dramatic effect on potency depending on the size and shape of the side chain. Cocrystal structures of inhibitors with wild-type HIV-1 protease revealed that the bis-THF moiety retained similar interactions as observed in the darunavir-protease complex regardless of the position on the Phe-Phe isostere. Analyses of cocrystal structures and molecular dynamics simulations provide insights into optimizing HIV-1 PIs containing bis-THF in non-sulfonamide dipeptide isosteres.

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors

A matched and mixed capping SAR study was conducted on the tetracyclic indole class of HCV NS5A inhibitors to examine the influence of modifications of this region on the overall HCV virologic resistance profiles.

Benzimidazole-imidazole Derivatives

Inhibitors of HCV replication of formula I including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R′ are, each independently, —CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES

Inhibitors of HCV replication of formula (I) including stereochemically isomeric forms, and salts, solvates thereof, wherein R and R' are, each independently,-CR1R2R3, aryl, heteroaryl or heteroC4-6cycloalkyl, whereby aryl and heteroaryl may optionally be substituted with 1 or 2 substituents selected from halo and methyl. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

LINKED DIBENZIMIDAZOLE DERIVATIVES

The present invention discloses linked dibenzimidazole derivatives, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Anti-Viral Compounds

Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV protease inhibiting compounds

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.